[Recombinant factor VIIa for the treatment of exsanguinating trauma patients: a matched-pair analysis from the Trauma Registry of the German Society for Trauma Surgery]. / Rekombinanter Faktor VIIa in der Hämorrhagiebehandlung des Schwerstverletzten: Eine Matched-pair-Analyse anhand des TraumaRegisters der Deutschen Gesellschaft für Unfallchirurgie.
Unfallchirurg
; 116(6): 524-30, 2013 Jun.
Article
em De
| MEDLINE
| ID: mdl-22699315
ABSTRACT
BACKGROUND:
The aim of the study was to assess whether the use of recombinant factor VIIa (rFVIIa) in trauma patients was associated with improved outcome. PATIENTS ANDMETHODS:
Patients documented in the TraumaRegistry of the German Society for Trauma Surgery (primary admissions; Injury Severity Score, ISS ≥ 9) who received rFVIIa in the first 6 hours upon admission (rFVIIa +) were matched with patients that had not received rFVIIa (rFVIIa-).RESULTS:
The matching comparison yielded two identical groups with 100 patients each (rFVIIa+ average age 40.6 ± 18.5 years, ISS 47.1 ± 16.7 versus rFVIIa- 40.1 ± 19.1 years, ISS 45.1 ± 15.6). Patients were administered an average of 18.3 ± 13.1 (rFVIIa+) versus 19.5 ± 14.0 (rFVIIa-) red blood cell units (p = 0.55) and 15.2 ± 13.7 (rFVIIa+) versus 15.0 ± 13.1 (rFVIIa-) units of fresh frozen plasma (p = 0.92). Thromboembolisms occurred in 5% (rFVIIa+) versus 2% (rFVIIa-) (p = 0.44), multiple organ failure (MOF) in 82% versus 62% (p = 0.003) and hospital mortality was 48% versus 43% (p = 0.57), respectively.CONCLUSION:
The early use of rFVIIa in severely injured patients was not associated with either lower transfusion requirements or with mortality reduction but with increased MOF.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Ferimentos e Lesões
/
Transfusão de Sangue
/
Fator VIIa
/
Sistema de Registros
/
Exsanguinação
Tipo de estudo:
Prevalence_studies
/
Risk_factors_studies
Limite:
Adult
/
Female
/
Humans
/
Male
País como assunto:
Europa
Idioma:
De
Ano de publicação:
2013
Tipo de documento:
Article